Stock Events

Stock Events

Ypsomed 

CHF278.55
16
-CHF2.45-0.87% Thursday 17:28

Statistics

Day High
281
Day Low
275.5
52W High
375.5
52W Low
179
Volume
348
Avg. Volume
-
Mkt Cap
0
P/E Ratio
1.71
Dividend Yield
0.39%
Dividend
1.1

Upcoming

6
JUL
Dividend Ex
Estimated
 
10
JUL
Dividend Payment
Estimated
 
5
JUL 27
Dividend Ex
Estimated
 
9
JUL 27
Dividend Payment
Estimated
 

Dividends

0.39%Dividend Yield
Jul 25
CHF1.1
Jul 24
CHF1
Jul 23
CHF0.65
Jul 22
CHF0.3
Jul 21
CHF0.58
10Y Growth
N/A
5Y Growth
13.66%
3Y Growth
19.17%
1Y Growth
N/A

Earnings

20MayExpected
Q1 2023
Q3 2023
Q1 2024
Q3 2024
Q1 2025
Q3 2025
Next
2.5
5.08
7.66
10.24
Expected EPS
6.006048
Actual EPS
N/A

Financials

11.68%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
1.5BRevenue
175.01MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0QLQ.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap116.33B
Medtronic is a major player in the medical device industry, competing directly with Ypsomed in the diabetes care market, particularly in insulin pump technology.
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Tandem Diabetes Care specializes in insulin pump technology and diabetes management solutions, directly competing with Ypsomed's offerings.
Insulet
PODD
Mkt Cap22.03B
Insulet Corporation is known for its Omnipod Insulin Management System, a direct competitor to Ypsomed's insulin pump products.
Dexcom
DXCM
Mkt Cap22.71B
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems, competing in the broader diabetes management space alongside Ypsomed.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers a range of healthcare products including the FreeStyle Libre, a CGM system, competing in the diabetes care market.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a leading global healthcare company that, while primarily known for insulin production, competes in the diabetes care market with devices and solutions.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is involved in diabetes care through its insulin and glucose monitoring solutions, making it a competitor in the broader diabetes management market.
Smith & Nephew
SNN
Mkt Cap15.61B
Smith & Nephew plc competes in the medical device sector, offering products that can indirectly compete with Ypsomed's portfolio in certain healthcare settings.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific Corporation competes in the medical device industry, offering products that can compete with Ypsomed's in terms of diabetes care and management solutions.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its medical devices segment, competes across a broad range of healthcare products, including those that can impact the diabetes care market.

About

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Show more...
CEO
Mr. Simon Michel
Employees
2644
Country
CH
ISIN
CH0019396990

Listings

LSE
GB
0QLQ.LSE
F
DE
OWX.F
OTC Link
US
YPHDF
SW
CH
YPSN.SW

0 Comments

Share your thoughts

FAQ

What is Ypsomed stock price today?▼
The current price of 0QLQ.LSE is CHF278.55 CHF — it has decreased by -0.87% in the past 24 hours. Watch Ypsomed stock price performance more closely on the chart.
What is Ypsomed stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ypsomed stocks are traded under the ticker 0QLQ.LSE.
Is Ypsomed stock price growing?▼
0QLQ.LSE stock has fallen by -0.46% compared to the previous week, the month change is a +1.13% rise, over the last year Ypsomed has showed a -12.27% decrease.
When is the next Ypsomed earnings date?▼
Ypsomed is going to release the next earnings report on May 20, 2026.
What were Ypsomed earnings last quarter?▼
0QLQ.LSE earnings for the last quarter are 10.24 CHF per share, whereas the estimation was 9.15 CHF resulting in a +11.86% surprise. The estimated earnings for the next quarter are N/A CHF per share.
What is Ypsomed revenue for the last year?▼
Ypsomed revenue for the last year amounts to 1.5B CHF.
What is Ypsomed net income for the last year?▼
0QLQ.LSE net income for the last year is 175.01M CHF.
Does Ypsomed pay dividends?▼
Yes, 0QLQ.LSE dividends are paid annual. The last dividend per share was 1.1 CHF. As of today, Dividend Yield (FWD)% is 0.39%.
How many employees does Ypsomed have?▼
As of April 05, 2026, the company has 2,644 employees.
In which sector is Ypsomed located?▼
Ypsomed operates in the Industrials sector.
When did Ypsomed complete a stock split?▼
Ypsomed has not had any recent stock splits.
Where is Ypsomed headquartered?▼
Ypsomed is headquartered in Burgdorf, CH.